Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

Press releases published on April 13, 2026

Apr. 13, 2026

Epitopea renforce son comité consultatif scientifique avec la nomination de Lisa Butterfield, figure de renom dans le domaine du cancer

Indeterminate GlobeNewswire

Apr. 13, 2026

Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows

Indeterminate GlobeNewswire

Apr. 13, 2026

Rising UK Dental Costs and NHS Access Crisis Drive Record Demand for Treatment in Türkiye — DentSpa Leads the Response

Indeterminate GlobeNewswire

Apr. 13, 2026

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Indeterminate GlobeNewswire

Apr. 13, 2026

Transgene annonce la fin de la randomisation des patients de la partie Phase 2 de l’essai clinique évaluant TG4050 dans le traitement adjuvant des cancers de la tête et du cou

Indeterminate GlobeNewswire

Apr. 13, 2026

SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)

Indeterminate GlobeNewswire

Apr. 13, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria

Indeterminate GlobeNewswire

Apr. 13, 2026

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants

Indeterminate GlobeNewswire

Apr. 13, 2026

Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)

Indeterminate GlobeNewswire

Apr. 13, 2026

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Indeterminate GlobeNewswire